Explore
Validate
Learn
Western blot
ImmunocytochemistryAntibody data
- Antibody Data
- Antigen structure
- References [17]
- Comments [0]
- Validations
- Western blot [1]
- Immunocytochemistry [1]
- Immunohistochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- AMAb90655 - Provider product page
- Provider
- Atlas Antibodies
- Proper citation
- Atlas Antibodies Cat#AMAb90655, RRID:AB_2665621
- Product name
- Anti-RBM3
- Antibody type
- Monoclonal
- Description
- Monoclonal Antibody against Human RBM3, Clone ID: CL0296, Gene description: RNA binding motif (RNP1, RRM) protein 3, Alternative Gene Names: IS1-RNPL, Validated applications: WB, IHC, ICC, Uniprot ID: P98179, Storage: Store at +4°C for short term storage. Long time storage is recommended at -20°C.
- Reactivity
- Human
- Host
- Mouse
- Conjugate
- Unconjugated
- Isotype
- IgG
- Antibody clone number
- CL0296
- Vial size
- 100 µl
- Concentration
- 0.1 mg/ml
- Storage
- Store at +4°C for short term storage. Long time storage is recommended at -20°C.
- Handling
- The antibody solution should be gently mixed before use.
Submitted references Transport of CLCA2 to the nucleus by extracellular vesicles controls keratinocyte survival and migration
Delineating the intra-patient heterogeneity of molecular alterations in treatment-naïve colorectal cancer with peritoneal carcinomatosis
Pre-clinical and clinical studies on the role of RBM3 in muscle-invasive bladder cancer: longitudinal expression, transcriptome-level effects and modulation of chemosensitivity
Comprehensive analysis of RNA binding motif protein 3 (RBM3) in non‐small cell lung cancer
Translational study reveals a two-faced role of RBM3 in pancreatic cancer and suggests its potential value as a biomarker for improved patient stratification
Podocalyxin-like and RNA-binding motif protein 3 are prognostic biomarkers in urothelial bladder cancer: a validatory study
Evaluation of RNA-binding motif protein 3 expression in urothelial carcinoma of the bladder: an immunohistochemical study
Low RBM3 Protein Expression Correlates with Clinical Stage, Prognostic Classification and Increased Risk of Treatment Failure in Testicular Non-Seminomatous Germ Cell Cancer
Evaluating real-time immunohistochemistry on multiple tissue samples, multiple targets and multiple antibody labeling methods
Decreased expression of RNA-binding motif protein 3 correlates with tumour progression and poor prognosis in urothelial bladder cancer
Evaluating real-time immunohistochemistry on multiple tissue samples, multiple targets and multiple antibody labeling methods
High MCM3 expression is an independent biomarker of poor prognosis and correlates with reduced RBM3 expression in a prospective cohort of malignant melanoma
Low RBM3 protein expression correlates with tumour progression and poor prognosis in malignant melanoma: An analysis of 215 cases from the Malmö Diet and Cancer Study
High RBM3 expression in prostate cancer independently predicts a reduced risk of biochemical recurrence and disease progression
High nuclear RBM3 expression is associated with an improved prognosis in colorectal cancer
RBM3-regulated genes promote DNA integrity and affect clinical outcome in epithelial ovarian cancer.
Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer
Seltmann K, Hettich B, Abele S, Gurri S, Mantella V, Leroux J, Werner S
Journal of Extracellular Vesicles 2024;13(4)
Journal of Extracellular Vesicles 2024;13(4)
Delineating the intra-patient heterogeneity of molecular alterations in treatment-naïve colorectal cancer with peritoneal carcinomatosis
Siesing C, Petersson A, Ulfarsdottir T, Chattopadhyay S, Nodin B, Eberhard J, Brändstedt J, Syk I, Gisselsson D, Jirström K
Modern Pathology 2022;35(7):979-988
Modern Pathology 2022;35(7):979-988
Pre-clinical and clinical studies on the role of RBM3 in muscle-invasive bladder cancer: longitudinal expression, transcriptome-level effects and modulation of chemosensitivity
Wahlin S, Boman K, Moran B, Nodin B, Gallagher W, Karnevi E, Jirström K
BMC Cancer 2022;22(1)
BMC Cancer 2022;22(1)
Comprehensive analysis of RNA binding motif protein 3 (RBM3) in non‐small cell lung cancer
Salomonsson A, Micke P, Mattsson J, La Fleur L, Isaksson J, Jönsson M, Nodin B, Botling J, Uhlén M, Jirström K, Staaf J, Planck M, Brunnström H
Cancer Medicine 2020;9(15):5609-5619
Cancer Medicine 2020;9(15):5609-5619
Translational study reveals a two-faced role of RBM3 in pancreatic cancer and suggests its potential value as a biomarker for improved patient stratification
Karnevi E, Dror L, Mardinoglu A, Elebro J, Heby M, Olofsson S, Nodin B, Eberhard J, Gallagher W, Uhlén M, Jirström K
Oncotarget 2017;9(5):6188-6200
Oncotarget 2017;9(5):6188-6200
Podocalyxin-like and RNA-binding motif protein 3 are prognostic biomarkers in urothelial bladder cancer: a validatory study
Boman K, Andersson G, Wennersten C, Nodin B, Ahlgren G, Jirström K
Biomarker Research 2017;5(1)
Biomarker Research 2017;5(1)
Evaluation of RNA-binding motif protein 3 expression in urothelial carcinoma of the bladder: an immunohistochemical study
Florianova L, Xu B, Traboulsi S, Elmansi H, Tanguay S, Aprikian A, Kassouf W, Brimo F
World Journal of Surgical Oncology 2015;13(1)
World Journal of Surgical Oncology 2015;13(1)
Low RBM3 Protein Expression Correlates with Clinical Stage, Prognostic Classification and Increased Risk of Treatment Failure in Testicular Non-Seminomatous Germ Cell Cancer
Ho Y, Olofsson S, Nodin B, Gaber A, Eberhard J, Uhlén M, Jirström K, Jerkeman M
PLOS ONE 2015;10(3):e0121300
PLOS ONE 2015;10(3):e0121300
Evaluating real-time immunohistochemistry on multiple tissue samples, multiple targets and multiple antibody labeling methods
Dubois L, Andersson K, Asplund A, Björkelund H
BMC Research Notes 2013;6(1)
BMC Research Notes 2013;6(1)
Decreased expression of RNA-binding motif protein 3 correlates with tumour progression and poor prognosis in urothelial bladder cancer
Boman K, Segersten U, Ahlgren G, Eberhard J, Uhlén M, Jirström K, Malmström P
BMC Urology 2013;13(1)
BMC Urology 2013;13(1)
Evaluating real-time immunohistochemistry on multiple tissue samples, multiple targets and multiple antibody labeling methods
Dubois L, Andersson K, Asplund A, Björkelund H
BMC Research Notes 2013 ;6(1):542
BMC Research Notes 2013 ;6(1):542
High MCM3 expression is an independent biomarker of poor prognosis and correlates with reduced RBM3 expression in a prospective cohort of malignant melanoma
Nodin B, Fridberg M, Jonsson L, Bergman J, Uhlén M, Jirström K
Diagnostic Pathology 2012;7(1)
Diagnostic Pathology 2012;7(1)
Low RBM3 protein expression correlates with tumour progression and poor prognosis in malignant melanoma: An analysis of 215 cases from the Malmö Diet and Cancer Study
Jonsson L, Bergman J, Nodin B, Manjer J, Pontén F, Uhlén M, Jirström K
Journal of Translational Medicine 2011;9(1)
Journal of Translational Medicine 2011;9(1)
High RBM3 expression in prostate cancer independently predicts a reduced risk of biochemical recurrence and disease progression
Jonsson L, Gaber A, Ulmert D, Uhlén M, Bjartell A, Jirström K
Diagnostic Pathology 2011;6(1)
Diagnostic Pathology 2011;6(1)
High nuclear RBM3 expression is associated with an improved prognosis in colorectal cancer
Hjelm B, Brennan D, Zendehrokh N, Eberhard J, Nodin B, Gaber A, Pontén F, Johannesson H, Smaragdi K, Frantz C, Hober S, Johnson L, Påhlman S, Jirström K, Uhlen M
PROTEOMICS – Clinical Applications 2011;5(11-12):624-635
PROTEOMICS – Clinical Applications 2011;5(11-12):624-635
RBM3-regulated genes promote DNA integrity and affect clinical outcome in epithelial ovarian cancer.
Ehlén Å, Nodin B, Rexhepaj E, Brändstedt J, Uhlén M, Alvarado-Kristensson M, Pontén F, Brennan DJ, Jirström K
Translational oncology 2011 Aug;4(4):212-21
Translational oncology 2011 Aug;4(4):212-21
Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer
Ehlén Å, Brennan D, Nodin B, O'Connor D, Eberhard J, Alvarado-Kristensson M, Jeffrey I, Manjer J, Brändstedt J, Uhlén M, Pontén F, Jirström K
Journal of Translational Medicine 2010;8(1)
Journal of Translational Medicine 2010;8(1)
No comments: Submit comment
Enhanced validation
- Submitted by
- Atlas Antibodies (provider)
- Enhanced method
- Genetic validation
- Main image
- Experimental details
- Western blot analysis in U-251MG cells transfected with control siRNA, target specific siRNA probe #1 and #2, using Anti-RBM3 antibody. Remaining relative intensity is presented. Loading control: Anti-GAPDH.
- Sample type
- Human
- Protocol
- Protocol
Supportive validation
- Submitted by
- Atlas Antibodies (provider)
- Main image
- Experimental details
- Immunofluorescence staining of U-2 OS cells using the anti-RBM3 monoclonal antibody, showing specific staining in the nucleoplasm in green. Microtubule- and nuclear probes are visualized in red and blue, respectively (where available).
- Sample type
- Human
Supportive validation
- Submitted by
- Atlas Antibodies (provider)
- Enhanced method
- Orthogonal validation
- Main image
- Experimental details
- Immunohistochemistry analysis in human tonsil and liver tissues using AMAb90655 antibody. Corresponding RBM3 RNA-seq data are presented for the same tissues.
- Sample type
- Human
- Protocol
- Protocol
